• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

γ-干扰素释放试验T-SPOT.TB在连续检测中的高重复性。

High reproducibility of the interferon-gamma release assay T-SPOT.TB in serial testing.

作者信息

Meier Thomas, Enders Martin

机构信息

Laboratory Prof. Gisela Enders and colleagues, MVZ, Rosenbergstrasse 85, D-70193, Stuttgart, Germany.

出版信息

Eur J Clin Microbiol Infect Dis. 2021 Jan;40(1):85-93. doi: 10.1007/s10096-020-03997-3. Epub 2020 Aug 8.

DOI:10.1007/s10096-020-03997-3
PMID:32770282
Abstract

Longitudinal studies regarding the reproducibility of Interferon-gamma release assay (IGRA) T-SPOT.TB for the diagnosis of Mycobacterium tuberculosis (M. tb) infection in serial testing are limited. We retrospectively analysed results of serially tested subjects in a medical laboratory in Germany over a time period of 14 years. From October 2004 to December 2018, a total of 5440 subjects were identified with a second T-SPOT.TB test after a median time interval of 258 days (interquartile range [IQR] 62-665). Consistently negative (n = 4520) or positive results (n = 682) were observed in 5202 (95.6%) subjects, indicating a high degree of concordance in serial testing (κ = 0.83). Test conversions occurred in 101 of 4621 (2.2%) subjects with initially negative tests. Of 819 subjects with initially positive test results, 137 (16.7%) had a test reversion which was associated with low spot numbers of the first test. Of 529 subjects retested within 1 year, only 60 (11.3%) displayed a test reversion. In subjects retested after more than 1 year, 77 of 290 (26.6%) tests reverted. This significantly higher rate of test reversions after more than 1 year was age-dependent and only observed in subjects above the age of 40 years. In the medical laboratory, the T-SPOT.TB test demonstrates a high reproducibility in serial testing.

摘要

关于干扰素-γ释放试验(IGRA)T-SPOT.TB在系列检测中诊断结核分枝杆菌(M. tb)感染的可重复性的纵向研究有限。我们回顾性分析了德国一家医学实验室14年间系列检测受试者的结果。从2004年10月至2018年12月,共识别出5440名受试者在中位时间间隔258天(四分位间距[IQR] 62 - 665)后进行了第二次T-SPOT.TB检测。在5202名(95.6%)受试者中观察到持续阴性(n = 4520)或阳性结果(n = 682),表明系列检测具有高度一致性(κ = 0.83)。4621名初始检测为阴性的受试者中有101名(2.2%)发生检测结果转换。在819名初始检测结果为阳性的受试者中,137名(16.7%)检测结果逆转,这与首次检测的斑点数较低有关。在1年内重新检测的529名受试者中,只有60名(11.3%)检测结果逆转。在1年后重新检测的受试者中,290名中有77名(26.6%)检测结果逆转。1年后这种显著更高的检测结果逆转率与年龄相关,且仅在40岁以上的受试者中观察到。在医学实验室中,T-SPOT.TB检测在系列检测中显示出高可重复性。

相似文献

1
High reproducibility of the interferon-gamma release assay T-SPOT.TB in serial testing.γ-干扰素释放试验T-SPOT.TB在连续检测中的高重复性。
Eur J Clin Microbiol Infect Dis. 2021 Jan;40(1):85-93. doi: 10.1007/s10096-020-03997-3. Epub 2020 Aug 8.
2
Reproducibility of the T-SPOT.TB test for screening Mycobacterium tuberculosis infection in Japan.日本结核分枝杆菌感染筛查中 T-SPOT.TB 试验的可重复性。
J Infect Chemother. 2020 Feb;26(2):194-198. doi: 10.1016/j.jiac.2019.08.006. Epub 2019 Sep 5.
3
Interferon gamma release assays for monitoring the response to treatment for tuberculosis: A systematic review.用于监测结核病治疗反应的干扰素γ释放试验:一项系统评价。
Tuberculosis (Edinb). 2015 Dec;95(6):639-650. doi: 10.1016/j.tube.2015.07.002. Epub 2015 Jul 30.
4
Interferon-Gamma Release Assay is Not Appropriate for the Diagnosis of Active Tuberculosis in High-Burden Tuberculosis Settings: A Retrospective Multicenter Investigation.干扰素-γ 释放试验不适用于高负担结核病环境中活动性结核病的诊断:一项回顾性多中心研究。
Chin Med J (Engl). 2018 Feb 5;131(3):268-275. doi: 10.4103/0366-6999.223860.
5
Serial testing for latent tuberculosis infection in transplant candidates: a retrospective review.移植候选者中潜伏性结核感染的系列检测:一项回顾性研究。
Transpl Infect Dis. 2016 Feb;18(1):14-21. doi: 10.1111/tid.12489. Epub 2016 Feb 3.
6
Position statement on interferon-γ release assays for the detection of latent tuberculosis infection.关于用于检测潜伏性结核感染的γ-干扰素释放试验的立场声明。
Commun Dis Intell Q Rep. 2017 Dec 1;41(4):E322-E336.
7
T-SPOT.TB Interferon-γ Release Assay Performance in Healthcare Worker Screening at Nineteen U.S. Hospitals.T-SPOT.TB 干扰素-γ 释放检测在 19 家美国医院医护人员筛查中的性能。
Am J Respir Crit Care Med. 2015 Aug 1;192(3):367-73. doi: 10.1164/rccm.201501-0199OC.
8
Performance of commercial blood tests for the diagnosis of latent tuberculosis infection in children and adolescents.用于诊断儿童和青少年潜伏性结核感染的商用血液检测的性能
Pediatrics. 2009 Mar;123(3):e419-24. doi: 10.1542/peds.2008-1722.
9
Contribution of a heparin-binding haemagglutinin interferon-gamma release assay to the detection of Mycobacterium tuberculosis infection in HIV-infected patients: comparison with the tuberculin skin test and the QuantiFERON-TB Gold In-tube.一种肝素结合血凝素干扰素-γ释放试验对检测HIV感染患者结核分枝杆菌感染的贡献:与结核菌素皮肤试验和全血γ-干扰素释放试验(QFT-GIT)的比较
BMC Infect Dis. 2015 Feb 14;15:59. doi: 10.1186/s12879-015-0796-0.
10
Serial testing of Mycobacterium tuberculosis infection in Chinese village doctors by QuantiFERON-TB Gold Plus, QuantiFERON-TB Gold in-Tube and T-SPOT.TB.中国乡村医生中结核分枝杆菌感染的 QuantiFERON-TB Gold Plus、QuantiFERON-TB Gold in-Tube 和 T-SPOT.TB 系列检测。
J Infect. 2019 Apr;78(4):305-310. doi: 10.1016/j.jinf.2019.01.008. Epub 2019 Jan 30.

引用本文的文献

1
Overlooked, dismissed, and downplayed: reversion of immunoreactivity.被忽视、被轻视和被淡化:免疫反应的逆转。
Eur Respir Rev. 2024 Jul 24;33(173). doi: 10.1183/16000617.0007-2024. Print 2024 Jul.
2
Monitoring islet specific immune responses in type 1 diabetes clinical immunotherapy trials.监测 1 型糖尿病临床免疫治疗试验中的胰岛特异性免疫反应。
Front Immunol. 2023 May 22;14:1183909. doi: 10.3389/fimmu.2023.1183909. eCollection 2023.

本文引用的文献

1
Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children.美国胸科学会/美国传染病学会/疾病控制与预防中心官方临床实践指南:成人及儿童结核病的诊断
Clin Infect Dis. 2017 Jan 15;64(2):111-115. doi: 10.1093/cid/ciw778.
2
Interferon Gamma Release Assays for Latent Tuberculosis: What Are the Sources of Variability?用于潜伏性结核的干扰素γ释放试验:变异性的来源有哪些?
J Clin Microbiol. 2016 Apr;54(4):845-50. doi: 10.1128/JCM.02803-15. Epub 2016 Jan 13.
3
Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.
潜伏性结核分枝杆菌感染的管理:世界卫生组织针对结核病低负担国家的指南
Eur Respir J. 2015 Dec;46(6):1563-76. doi: 10.1183/13993003.01245-2015. Epub 2015 Sep 24.
4
T-SPOT.TB Interferon-γ Release Assay Performance in Healthcare Worker Screening at Nineteen U.S. Hospitals.T-SPOT.TB 干扰素-γ 释放检测在 19 家美国医院医护人员筛查中的性能。
Am J Respir Crit Care Med. 2015 Aug 1;192(3):367-73. doi: 10.1164/rccm.201501-0199OC.
5
Latent tuberculosis infection: myths, models, and molecular mechanisms.潜伏性结核感染:误区、模型及分子机制
Microbiol Mol Biol Rev. 2014 Sep;78(3):343-71. doi: 10.1128/MMBR.00010-14.
6
Interferon-γ release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States.干扰素-γ 释放试验与结核菌素皮肤试验用于美国医护人员潜伏性结核感染的诊断。
Am J Respir Crit Care Med. 2014 Jan 1;189(1):77-87. doi: 10.1164/rccm.201302-0365OC.
7
Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review.干扰素-γ检测结果在结核病中的个体内变异性和结核菌素皮肤试验的增强效应:系统评价。
PLoS One. 2009 Dec 30;4(12):e8517. doi: 10.1371/journal.pone.0008517.
8
A 100 year update on diagnosis of tuberculosis infection.关于结核感染诊断的 100 年更新。
Br Med Bull. 2010;93:69-84. doi: 10.1093/bmb/ldp039. Epub 2009 Nov 18.
9
Evaluation of an interferon-gamma release assay, T-SPOT.TB, in a population with a low prevalence of tuberculosis.评价一种低结核感染率人群中干扰素 - γ 释放试验,T-SPOT.TB。
Int J Tuberc Lung Dis. 2009 Nov;13(11):1416-21.
10
Sensitivity of IFN-gamma release assay to detect latent tuberculosis infection is retained in HIV-infected patients but dependent on HIV/AIDS progression.干扰素-γ释放试验检测潜伏性结核感染的敏感性在HIV感染患者中得以保留,但取决于HIV/AIDS的进展情况。
PLoS One. 2008 Jan 16;3(1):e1441. doi: 10.1371/journal.pone.0001441.